Sardanelli Francesco, Aase Hildegunn S, Álvarez Marina, Azavedo Edward, Baarslag Henk J, Balleyguier Corinne, Baltzer Pascal A, Beslagic Vanesa, Bick Ulrich, Bogdanovic-Stojanovic Dragana, Briediene Ruta, Brkljacic Boris, Camps Herrero Julia, Colin Catherine, Cornford Eleanor, Danes Jan, de Geer Gérard, Esen Gul, Evans Andrew, Fuchsjaeger Michael H, Gilbert Fiona J, Graf Oswald, Hargaden Gormlaith, Helbich Thomas H, Heywang-Köbrunner Sylvia H, Ivanov Valentin, Jónsson Ásbjörn, Kuhl Christiane K, Lisencu Eugenia C, Luczynska Elzbieta, Mann Ritse M, Marques Jose C, Martincich Laura, Mortier Margarete, Müller-Schimpfle Markus, Ormandi Katalin, Panizza Pietro, Pediconi Federica, Pijnappel Ruud M, Pinker Katja, Rissanen Tarja, Rotaru Natalia, Saguatti Gianni, Sella Tamar, Slobodníková Jana, Talk Maret, Taourel Patrice, Trimboli Rubina M, Vejborg Ilse, Vourtsis Athina, Forrai Gabor
Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Department of Radiology, Research Hospital Policlinico San Donato, Via Morandi 30, 20097, San Donato Milanese, Milan, Italy.
Eur Radiol. 2017 Jul;27(7):2737-2743. doi: 10.1007/s00330-016-4612-z. Epub 2016 Nov 2.
EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50-69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1-10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40-49 years and 70-74 years, although with "limited evidence". Thus, we firstly recommend biennial screening mammography for average-risk women aged 50-69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40-45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become "routine mammography" in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.
• EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50-69 years. • Extension to 73-75 and from 40-45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become "routine mammography" in the screening setting in the next future.
欧洲乳腺影像学会（EUSOBI）和30个国家的乳腺放射学机构支持基于人群的乳腺钼靶筛查，该筛查已被证明可降低乳腺癌（BC）死亡率及治疗影响。根据国际癌症研究机构的数据，接受邀请的50至69岁女性死亡率降低40%，而每轮假阳性针吸活检的概率<1%，20年筛查的过度诊断仅为1 - 10%。40至49岁和70至74岁年龄组也观察到死亡率降低，尽管“证据有限”。因此，我们首先建议对50至69岁的平均风险女性进行每两年一次的乳腺钼靶筛查；其次优先考虑将筛查年龄延长至73或75岁，每两年一次；第三优先考虑从40 - 45岁至49岁每年进行筛查。不鼓励使用热成像或其他光学工具作为乳腺钼靶的替代筛查方法。应优先选择基于地区的人群筛查项目，并进行双人阅片。优先采用数字乳腺钼靶（而非屏-片或磷板计算机放射摄影），这也提高了致密型乳腺的敏感性。具备筛查阅片资格的放射科医生应参与筛查项目。数字乳腺断层合成在未来也将成为筛查中的“常规乳腺钼靶检查”。鼓励根据国家或国际指南及建议为高危女性提供乳腺MRI的专门途径。
• 欧洲乳腺影像学会（EUSOBI）和30个国家的乳腺放射学机构支持乳腺钼靶筛查。• 首要优先事项是对50至69岁女性进行每两年一次的双人阅片乳腺钼靶检查。• 也鼓励将筛查年龄延长至73 - 75岁以及从40 - 45岁至49岁。• 应使用数字乳腺钼靶（而非屏-片或计算机放射摄影）。• 数字乳腺断层合成在未来将成为筛查中的“常规乳腺钼靶检查”。
